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Abstract
Epstein-Barr virus (EBV) is associated with human malignancies, especially those affecting the B cell compartment such as
Burkitt lymphoma. The virally encoded homolog of the mammalian pro-survival protein Bcl-2, BHRF1 contributes to viral
infectivity and lymphomagenesis. In addition to the pro-apoptotic BH3-only protein Bim, its key target in lymphoid cells,
BHRF1 also binds a selective sub-set of pro-apoptotic proteins (Bid, Puma, Bak) expressed by host cells. A consequence of
BHRF1 expression is marked resistance to a range of cytotoxic agents and in particular, we show that its expression renders
a mouse model of Burkitt lymphoma untreatable. As current small organic antagonists of Bcl-2 do not target BHRF1, the
structures of it in complex with Bim or Bak shown here will be useful to guide efforts to target BHRF1 in EBV-associated
malignancies, which are usually associated with poor clinical outcomes.
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Introduction
To combat invading viruses, altruistic suicide of the infected
host cells may be initiated to rapidly and efficiently eliminate the
pathogen [1,2]. Often, this response is a critical component of host
defences [1,2]. Consequently, many viruses have co-evolved
adaptive mechanisms to subvert apopt osis, thereby ensuring their
own survival and propagation. Some viruses, such as Epstein-Barr
virus (EBV), encode homologs of the mammalian pro-survival
protein Bcl-2 [3,4,5]. EBV was first identified in association with
Burkitt lymphoma and it is also linked to other lymphoid
malignancies (Hodgkin’s lymphoma, post-transplant lymphopro-
liferative disorders) and nasopharyngeal carcinoma [6]. Whereas
increased expression of Bcl-2 promotes malignancies such as
human follicular lymphoma [7], the precise role of the EBV
encoded Bcl-2 homolog BHRF1 in EBV-associated malignancies
is less well defined.
However, more recent studies link BHRF1 to the transforma-
tion of primary B lymphocytes [8] and to lymphomagenesis [9].
Since overactivity of the oncogene myc is obligatory for Burkitt
lymphoma [10,11,12], expression of BHRF1 may be necessary to
block myc-induced apoptosis, akin to the striking synergy observed
between Bcl-2 and myc during B cell transformation [13,14]. Of
note, the constitutive expression of BHRF1 permits lymphoblas-
toid immortalization by EBV and their prolonged survival [9], and
together with expression of BHRF1 during normal B cells
transformation [8] suggests a role for BHRF1 in post-transplant
lymphoproliferative disease. Although confirmed BHRF1 expres-
sion has been shown in only a subset of Burkitt lymphomas [9,15],
it is plausible that BHRF1 plays a central role in the maintenance
of this subset of Burkitt lymphomas as Bcl-2 overexpression is rare
in this disease.
As BHRF1 may be central for developing and maintaining
certain EBV-associated lymphomas, we investigated if BHRF1 can
modulate responses to therapy in experimental models. If so,
BHRF1 represents an attractive drug target since normal cells may
well be spared by its selective antagonism. Here, we show that
BHRF1 potently confers chemoresistance, and importantly, it
adversely impacts upon survival in a mouse model of Burkitt
lymphoma. BHRF1 acts by sequestering a subset of the pro-
apoptotic Bcl-2 family proteins; we show here the 3D structures of
it in complex with BH3 domains of two, Bim and Bak, which may
provide the basis for developing small molecule inhibitors of
BHRF1 to improve the generally poor prognosis in EBV-
associated malignancies.
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BHRF1 counters apoptosis induced by multiple
chemotherapeutic agents
Using cultured cell lines, we tested the ability of BHRF1 to
confer resistance against a range of apoptotic stimuli, especially
those used for cancer chemotherapy. Stable expression of BHRF1
in FDC-P1 mouse myelomonocytic cells conferred resistance to
etoposide or c-irradiation (Fig. 1A) comparable to that observed in
cells expressing similar levels of Bcl-2, Bcl-xL or Bcl-w (Fig. 1D). It
also inhibited apoptosis induced by other cytotoxics including
cytosine arabinoside (Ara-C), doxorubicin, etoposide and staur-
osporine in other cell lines (Figs. 1B, 1C, S1 and data not shown),
comparable to that observed in cells expressing similar levels of
Bcl-2 (Fig. 1E). Thus, BHRF1, like its mammalian counterparts,
inhibits apoptosis induced in multiple cell types by diverse
chemotherapeutic agents.
BHRF1 preserves mitochondrial function by inhibiting
the activation of Bax and Bak
To ascertain precisely how BHRF1 interferes with apoptosis
signaling, we examined mitochondrial outer membrane permea-
bilization (MOMP) [16] in FDC-P1 cells after treatment with
staurosporine. Whereas MOMP occurred rapidly in the parental
cells, as indicated by the reduced uptake of the mitochondrial dye
DiOC6(3), it was inhibited in cells expressing BHRF1 or Bcl-2
(Fig. 2A), implicating an anti-apoptotic effect upstream of
mitochondrial damage. When the mediators of mitochondrial
damage (Bax and Bak) were examined, we found that BHRF1
inhibited translocation of Bax from the cytosol (Fig. 2B) and
activation of Bax and Bak was abrogated, as their conformational
alteration associated with activation is blocked (Fig. 2C). Consis-
tent with these observations, BHRF1 also inhibited the release of
cytochrome c from within the mitochondria (Fig. 2B).
We conclude that BHRF1 must exert its anti-apoptotic effect at
the level of, or prior to, Bax and Bak activation, consistent with a
report that BHRF1 prevented Bax and Bak conformational
change, oligomerization and activation of the initiator caspase,
caspase-9 [17]. How then might BHRF1 inhibit activation of these
essential cell death mediators?
BHRF1 interacts with a sub-set of pro-apoptotic Bcl-2
family proteins
It is most likely that BHRF1 acts to abort cell death initiation by
sequestering the endogenous pro-apoptotic mammalian Bcl-2
family members. Thus, we assessed the ability of a recombinant
C-terminally truncated form of BHRF1 to directly bind
peptides spanning the BH3 domains of pro-apoptotic Bcl-2
proteins using isothermal titration calorimetry (ITC). Binding
was observed with peptides from the BH3-only proteins Bim
(KD=18 nM), Puma (70 nM) or Bid (110 nM) (Fig. 3A). No
detectable binding was observed with peptides from other BH3-
only proteins, or with Mule and Beclin-1, other proteins harboring
a BH3 domain. We confirmed the interaction of intact BHRF1 in
mammalian cells with selected full-length BH3-only proteins in co-
immunoprecipitation assays (Fig. 3B). These results closely mirror
those obtained in solution competition assays, using either
fluorescence polarization [18] or surface plasmon resonance
[19]. Thus, BHRF1 probably antagonizes a subset of the BH3-
only proteins by direct sequestration. Interestingly, the ones
targeted (Bid, Bim, Puma) are potent inducers of apoptosis, either
because they neutralize most, if not all, the mammalian pro-
survival proteins [20,21] or because they can directly activate Bax
or Bak [22,23,24].
We also investigated if BHRF1, in a manner similar to some
mammalian [21,25] and viral Bcl-2 proteins [26,27], might
directly bind Bax and Bak, the downstream mediators of
mitochondrial damage. Recombinant BHRF1 bound a 26-mer
Bak BH3 peptide (KD=150 nM), but only weakly (.1 mM) to
Bax BH3 (Fig. 3A). Consistent with the binding data, we observ-
ed that BHRF1 could directly counter Bak (Fig. 3C), but not Bax,
when these proteins were expressed in yeast [28]. This
heterologous model system is suited for studying the function-
al interactions by circumventing potential complications due to the
presence of endogenous Bcl-2 family proteins in mammalian
cells and avoids the use of detergents that may artificially induce or
disrupt interactions between Bcl-2 family proteins [29]. Our assay
is based on the observation that overexpression of Bax or Bak
in yeast is lethal, even though yeasts do not express Bcl-2
family members and do not undergo apoptosis. Nonetheless,
co-expression of Bcl-2, Bcl-xL, Mcl-1, or A1 with Bax and Bak can
suppress death induced in yeast [30], thus reconstituting key
aspects of the mammalian apoptotic machinery. Our observa-
tion that BHRF1 could counter Bak (Fig. 3C), but not Bax-
induced yeast death when these proteins were expressed in yeast
suggests that BHRF1 is only able to directly neutralize Bak, but
not Bax.
Taken together with the previous reports that BHRF1 interacts
with the full-length Bak, but not with Bax [17,31,32], we conclude
that BHRF1 can keep Bak inactive by direct binding (Fig. 3A, 3C,
[19]), but must inhibit Bax indirectly, presumably by its ability to
sequester BH3-only proteins such as Bim (Fig. 3A, 3B, [31]). It will
therefore be interesting to investigate which pro-apoptotic protein
is the critical target for BHRF1 in diverse cell types, especially
those targeted by EBV during oncogenesis. It is noteworthy that in
some lymphoid cells, the pro-survival action of BHRF1 tracked
with its ability to bind Bim [31], which is critical for apoptosis
induced by multiple stimuli in this cell type [33] and plays a role in
suppressing myc-driven lymphomagenesis [34].
Author Summary
Altruistic suicide of infected host cells is a key defense
mechanism to combat viral infection. To ensure their own
survival and proliferation, certain viruses, including Ep-
stein-Barr virus (EBV), have mechanisms to subvert
apoptosis, including the expression of homologs of the
mammalian pro-survival protein Bcl-2. EBV was first
identified in association with Burkitt lymphoma and it is
also linked to certain Hodgkin’s lymphomas and nasopha-
ryngeal carcinoma. Whereas increased expression of Bcl-2
promotes malignancies such as human follicular lympho-
ma, the precise role of the EBV encoded Bcl-2 homolog
BHRF1 in EBV-associated malignancies is less well defined.
BHRF1 is known to bind the pro-apoptotic BH3-only
protein Bim, and here we demonstrate that it also binds
other pro-apoptotic proteins (Bid, Puma, Bak) expressed by
host cells. Crystal structures of BHRF1 with the BH3 regions
of Bim and Bak illustrate these interactions in atomic detail.
A consequence of BHRF1 expression is marked resistance
to a range of cytotoxic agents, and we show that its
expression renders a mouse model of Burkitt lymphoma
untreatable. As current antagonists of Bcl-2 do not target
BHRF1, our crystal structures will be useful to guide efforts
to target BHRF1 in EBV-associated malignancies, which are
usually associated with poor clinical outcomes.
Epstein-Barr Virus BHRF1 and Chemoresistance
PLoS Pathogens | www.plospathogens.org 2 December 2010 | Volume 6 | Issue 12 | e1001236Figure 1. BHRF1 protects cells from diverse apoptotic stimuli. (A) Viability of FDC-P1 cells stably overexpressing BHRF1, Bcl-2, Bcl-xL, Bcl-w or
vector, treated with 0-10 mM etoposide (left) or 0–30 Gy c-irradiation (right) and cultured for 48 h. (B) Em-myc pre-B-cell tumor cells were stably
transfected with BHRF1, Bcl-2 or vector were exposed to 0–10 mM cytosine arabinoside (Ara-C) for 24 h. (C) MEFs overexpressing BHRF1, Bcl-2, Bcl-xL
or vector were treated with 0–100 mM etoposide for 24 h. (D) Bcl-2, Bcl-xL, Bcl-w and BHRF1 are expressed at comparable levels in FDC-P1 cells. FLAG-
tagged wild-type Bcl-2, Bcl-xL, Bcl-w and BHRF1 were stably expressed in FDC-P1 cells. Protein expression was evaluated using flow cytometry after
staining fixed cells with an anti-FLAG antibody, followed by an anti-mouse FITC secondary antibody. Controls (dotted lines) indicate staining of cells
expressing empty vector. (E) BHRF1 and Bcl-2 are expressed at comparable levels in Em-myc pre-B-cell tumor cells. Pre-B-cell tumor cells derived from
Em-myc transgenic mice were stably transfected with FLAG-tagged BHRF1, Bcl-2 or an empty control vector. Protein expression was evaluated using
flow cytometry after staining fixed cells with an anti-FLAG antibody, followed by an anti-mouse FITC secondary antibody. Controls (dotted lines)
indicate staining of cells expressing empty vector. Cell viability was determined by PI exclusion; data shown are means 61 SEM of 3 independent
experiments except for the representative c-irradiation experiment shown in (A).
doi:10.1371/journal.ppat.1001236.g001
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PLoS Pathogens | www.plospathogens.org 3 December 2010 | Volume 6 | Issue 12 | e1001236Figure 2. BHRF1 inhibits loss of mitochondrial transmembrane potential and Bax/Bak activation. (A) FDC-P1 cells expressing BHRF1, Bcl-
2 or a control vector were treated with 25 nM staurosporine for 24 h. Outer mitochondrial transmembrane potential (Dym) was assessed by DiOC6(3)
uptake. (B) HeLa cells treated with 200 J/m
2 UV-irradiation were analyzed at 4 h for Bax translocation and cytochrome c release by immunoblotting
after fractionation into soluble (s) and pellet (p) fractions. (C) Bax and Bak activation in UV-irradiated HeLa cells were assessed at 4 h using the
conformation-specific mouse anti-Bak clone Ab-1 (Calbiochem) or mouse anti-Bax clone 3 antibodies [53].
doi:10.1371/journal.ppat.1001236.g002
Figure 3. BHRF1 binds a subset of pro-apoptotic Bcl-2 family proteins to counter apoptosis. (A) The affinity of recombinant BHRF1DC31
for BH3 domain peptides (26-mers, except for a Bax 28-mer and a Bid 34-mer) was assessed using isothermal titration calorimetry (ITC). Kd values (in
nM) are the means of 3 experiments 6 SD. NB: no binding detected. (B) Lysates prepared from
35S-labeled HEK-293T cells co-expressing FLAG-tagged
BHRF1 and EE-tagged BH3-only proteins were immunoprecipitated with mouse monoclonal antibodies recognizing the FLAG (FL), EE, or an irrelevant
control (C) tag. **Endogenous 14-3-3 associating with Bad [56]. (C) Yeast co-transformed with constructs encoding Bax or Bak and the indicated pro-
survival proteins, each under the control of an inducible (GAL) promoter, were spotted onto inducing galactose (‘‘ON’’) or repressing glucose (‘‘OFF’’)
plates as 5-fold serial dilutions. Images are representative of 2 independent experiments.
doi:10.1371/journal.ppat.1001236.g003
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BHRF1
Our data (Fig. 3) and previously published studies [18] suggest
that BHRF1, like its mammalian counterparts, inhibits cell death
by sequestering endogenous pro-apoptotic Bcl-2 proteins. How-
ever, the structural basis for this is unclear since a previously
published structure of C-terminally truncated BHRF1 lacked the
characteristic hydrophobic surface groove responsible for interac-
tion with the BH3 domains [35]. We have therefore determined
crystal structures of BHRF1 in complex with its key targets, the
BH3 domains of Bim (Fig. 4A–B, Table 1) and Bak (Fig. 4C,
Table 1).
The Bim BH3 peptide binds into a surface groove formed by
helices a2-5 of BHRF1 (Fig. 4A), in a similar manner to that
previously observed for mammalian pro-survival Bcl-2 members
such as Bcl-xL [36] or the unrelated viral Bcl-2 protein M11L [27].
Bak BH3 binds in an equivalent manner (Fig. 4C), and the two
complexes superimpose with an RMSD of only 0.6 A ˚ over the
entire BHRF1 backbone indicating their similarities. As the
characteristic hydrophobic surface groove was absent in unli-
ganded BHRF1 due to the close proximity of helices a3 and a4
(Fig. 4E; [35]), significant structural changes are required in order
to accommodate Bim or Bak BH3 domains. These changes affect
mainly a4, which is at a 120u angle to a3 in the BH3-bound form
(Fig. 4A), compared to the near anti-parallel alignment in the free
form (Fig. 4E). Overall, the free and bound BHRF1 structures
(comparing Fig. 4A with 4B) superimpose with an RMSD of
3.5 A ˚, with most differences found within the BH3 binding
groove. This is reminiscent of the movement observed in Bcl-xL,
which in the ligand-free state displays a narrow binding groove
[37]. However, upon ligand binding, both a3 and 4 helices move
to widen the hydrophobic groove and allow binding [36]. In
contrast, the movement of a3 that enables groove opening in
BHRF1 upon ligand binding is much less pronounced.
The side-chain interactions contributing to the BHRF1-BH3
complexes are equivalent to those observed for mammalian pro-
survival proteins such as Bcl-xL, with the four conserved
hydrophobic BH3 residues of Bim (I58, L62, I65 and F69;
numbering based on human BimL) protruding into pockets within
the BHRF1 hydrophobic binding groove (Fig. 4G). Similarly, Bak
residues V74, L78, I81 and I85 (numbering based on human Bak)
interact with the BHRF1 binding groove (Fig. 4H). In addition to
the hydrophobic interactions, BHRF1 R100 forms a salt bridge
with Bim D67 or with Bak D83 (Fig. 4G, 4H). This electrostatic
interaction is also observed in complexes of Mcl-1 and Bcl-xL with
pro-apoptotic BH3 domains [36,38] and even in a complex of Bcl-
Figure 4. BH3 peptides bind BHRF1 in a canonical binding groove. (A–B) BHRF1 (blue) in complex with the Bim BH3 domain (yellow). BHRF1
helices are labeled a1, a19, a2-8. The view in (A) is into the hydrophobic binding groove formed by helices a3-5, while (B) is rotated by 180u through
the vertical axis to illustrate helix a19. (C) BHRF1 (blue) in complex with the Bak BH3 domain (orange). The view is as in (A). (D) Bcl-xL (cyan) in complex
with the Bim BH3 domain [36]. The view is as in (A). (E–F) Unliganded BHRF1 ([35]; in green). The view in (E) is similar to (A), while (F) is comparable to
(B). The binding groove is occluded by the near parallel arrangement of helices a3 and a4. (G) Detailed view of the BHRF1:Bim complex interface. The
BHRF1 surface, backbone and binding groove are shown in grey, cyan and magenta respectively, while Bim BH3 is shown in yellow. The four key
hydrophobic residues of Bim (I58, L62, I65 and F69; numbering based on human BimL) protruding into the binding groove, as well as the conserved
salt-bridge formed by Bim D67 and BHRF1 R100 are labeled. (H) Detailed view of the BHRF1:Bak complex interface. Colour scheme is as for (G) with
Bak BH3 shown in orange. The four key hydrophobic residues of Bak (V75, L78, I81 and I85) protruding into the BHRF1 binding groove, as well as the
conserved salt-bridge formed by Bak D83 and BHRF1 R100 are labeled.
doi:10.1371/journal.ppat.1001236.g004
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in the mammalian BH3 ligands suggests that this interaction is of
particular importance for complex formation, and indeed a
BHRF1 R100A mutation reduces Bim binding and abolishes
interaction with Bak [31].
BHRF1 confers potent chemoresistance in vivo
SinceBHRF1engagesBH3 domainsusing ahydrophobicgroove
(Fig. 4) in a manner equivalent to that of its mammalian
counterparts, conserving key interactions, we asked whether ABT-
737, a BH3 mimetic compound known to inhibit Bcl-2, Bcl-xL, and
Bcl-w [40,41], could also target BHRF1. In the absence of pro-
survival Mcl-1, ABT-737 is a potent cytotoxic agent. However, cells
expressing BHRF1 were completely insensitive to ABT-737, evenat
the highest dose tested (10 mM) (Fig. S2), and survived long-term
(Fig. 5A). Similarly, recombinant BHRF1 did not bind ABT-737 in
biosensor assays (IC50.20 mM, data not shown). As ABT-737 is
ineffective and as BHRF1 can potently confer chemoresistance
when tested in cultured cell lines (Fig. 1), we evaluated the impact of
its expression in a transgenic mouse model of Burkitt lymphoma
[11]. In the Em-myc mouse, myc is overexpressed in the B cell and
drives an aggressive B cell leukemia/lymphoma syndrome that is
very similar to human Burkitt lymphoma.
Malignant cells derived from sick Em-myc mice are readily
transplantable into syngeneic wild-type recipients which succumb
within four weeks to a disseminated disease if left untreated [42].
Treatment with Ara-C (Fig. 5C, black line), an agent used in the
clinic for treating patients with Burkitt lymphoma, resulted in a
sustained disease remission and survival with all mice alive and
disease-free at 100 days with normal peripheral blood counts and
spleen weights. In striking contrast, only a handful of treated mice
that were inoculated with tumor cells overexpressing BHRF1 or
Bcl-2 survive long-term (Fig. 5C). Comparable results were
observed when two other cytotoxic agents, cyclophosphamide
and etoposide, were used in similar efficacy studies (data not
shown). Therefore BHRF1, like Bcl-2 [42], can potently confer
chemoresistance in a mouse model of Burkitt lymphoma. Thus, it
is highly likely that expression of BHRF1 will attenuate the
response during treatment for EBV-driven malignancies.
Concluding remarks
In this study, we have confirmed that EBV BHRF1 exerts its
pro-survival function by directly inhibiting a sub-set of pro-
apoptotic Bcl-2 family proteins Bid, Bim, Puma and Bak,
presumably ones most critical for the virus. Our three-dimensional
structures show that these interactions closely resemble those seen
with mammalian pro-survival proteins such as Bcl-xL. In light of
the importance of BHRF1 in certain Burkitt lymphomas [9], and
its detection in other EBV-associated malignancies including
nasopharyngeal carcinoma [43] and B cell lymphomas [44], the
development of therapeutic inhibitors of BHRF1 may be highly
desirable. The inability of current small molecule inhibitors of
Table 1. Crystallographic statistics.
Crystal BHRF1:Bim BH3 BHRF1:Bim BH3 BHRF1:Bak BH3
Data collection and phasing Derivative MeHg Native Native
Spacegroup P3221 P3221 P3221
Resolution range (A ˚) 5 0-2 . 7 5 0–1 . 5 5 0-2 . 0 5
Unique reflections 6110 33924 13668
Multiplicity
a 7.2 (5.5) 9.6 (6.7) 10.0 (5.1)
Completeness (%)
a 99.1 (94.3) 98.8 (93.1) 99.5 (95.8)
I/sI 40.7 (2.4) 33.9 (2.2)
Rmerge
a,b 0.088 (0.346) 0.043 (0.568) 0.064 (0.497)
Rderiv
c 0.212
Rcullis (centric/acentric)
d 0.653/0.609
Phasing power (centric/acentric)
e 1.46/1.39
Refinement
Resolution range (A ˚) 50 – 1.5 20 - 2.05
Reflections (working set/test set) 32174/1705 12945/668
Protein atoms 1466 1437
Solvent atoms 116 H2O, 9 Br 73 H2O, 4 NO3
Rcryst/Rfree
f 0.198/0.205 0.184/0.217
r.m.s.d. bonds (A ˚) 0.015 0.021
r.m.s.d. angles (u) 1.7 1.8
Ramachandran plot (%)
g 95.0/5.0/0.0/0.0 97.4/1.9/0.6/0.0
aNumbers in parentheses refer to the highest resolution shells.
bRmerge = ghgi |I i(h)-,I(h). |/ghgiIi(h), where Ii(h) is the ith measurement of reflection h and ,I(h). is the weighted mean of all measurements of h.
cRderiv = gh||FPH |-| F P||/gh|FP|, where FP and FPH are the native and derivative structure factors, respectively.
dRcullis = gh|||FPH|-| F P|| - |FH||/gh||FPH|-| F P|, where FH is the calculated heavy atom structure factor.
ePhasing power is defined as (r.m.s FH/r.m.s lack-of closure).
fR=gh|Fobs -F calc|/ghFobs, where Fobs and Fcalc are the observed and calculated structure factor amplitudes, respectively. Rcryst and Rfree were calculated using the
working and test set, respectively.
gResidues in most favoured, additionally allowed, generously allowed and disallowed regions.
doi:10.1371/journal.ppat.1001236.t001
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BHRF1 will require novel small molecule antagonists to be
developed. The successful development of small molecule
inhibitors of mammalian pro-survival Bcl-2 family proteins [40]
suggests that similar approaches might be applied to the
development of BHRF1 inhibitors.
Materials and Methods
Recombinant proteins and binding experiments
BHRF1DC31 was cloned into pET DUET (Invitrogen) using
BamHI and EcoRI, and expressed in E.coli BL21 DE3 pLysS. Cells
were homogenized using an Avestin EmulsiFlex homogenizer in lysis
buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 10 mM BME).
His-tagged BHRF1DC31 was purified using a nickel charged Hi-
Trap chelating column (Amersham), eluted in lysis buffer with
250 mM imidazole and subjected to gel-filtration chromatography in
25 mM Hepes pH 7.5, 150 mM NaCl using a Superdex 200 column
(GE Healthcare). Calorimetry data were collected on a VP-ITC
(MicroCal) with BHRF1DC31 as previously described [45]. All
peptides were purified by reverse-phase HPLC and dissolved as 2–
5 mM stock solutions in water. The accession numbers for the
peptides were: human BimL (AAC39594), human Puma
(AAK39542), mouse Bmf (AAK38747), human Bad (NP_004313),
human Bik (NP_001188), human Hrk (NP_003797), human Bid
(NP_001187), human Noxa (NP_066950), human Bax (NP_620119),
human Bak (NP_001179), mouse Mule (UniProt Accession code
Q7TMY8; residues 1969–1994; PGGTTQEVGQLLQDMGDD-
VYQQYRSL) and mmBeclin (UniProt Accession code O88597,
residue 103–128; DGGTMENLSRRLKVTGDLFDIMSGQT).
Crystallization and structure determination
BHRF1 complexes with Bim or Bak BH3 were obtained by
mixing BHRF1 with human Bim or Bak 26-mer peptide in a
1:1.25 molar ratio and concentrating using a centricon (Millipore)
to 10 mg/mL. Crystals were grown in sitting drops at 20uCi n
1.2 M NaBr, 50 mM malic acid pH 4.0 (BHRF1:Bim) or 1.6 M
NaNO3, 50 mM malic acid pH 4.4 (BHRF1:Bak). The crystals
belong to space group P3221 with a=b=62.75 A ˚, c=92.38 A ˚,
a=b=90u, c=120u (BHRF1:Bim) or a=b=62.39 A ˚, c=93.73
A ˚, a=b=90u, c=120u (BHRF1:Bak). The asymmetric units
contain 1 BHRF1:peptide complex. Diffraction data were
collected from flash frozen crystals at 100 K at the Australian
Synchrotron (beamline 3BM1) or at the Swiss Light Source
(beamlines X06SA, X10SA) and processed with HKL2000. For
the BHRF1:Bim complex, a heavy atom derivative was obtained
by soaking crystals in mother liquor supplemented with 1 mM
MeHgCl for 2 h. Hg sites were found and refined with Sharp.
Clear and continuous electron density was obtained for residues 2–
158 of BHRF1 and 51–72 of Bim. The final model was built with
Coot [46], refined with Refmac5 [47] to a resolution of 1.5 A ˚ and
has a final R-factor of 0.198 (R-free 0.205). 95.0% of the residues
are in the core regions of the Ramachandran plot, and no residues
are in disallowed regions.
The BHRF1:Bak structure was solved by molecular replace-
ment with PHASER [48] using the BHRF1:Bim structure as a
search model. The final model was built with Coot and refined
with Refmac5 to a resolution of 2.05 A ˚ and has a final R-factor of
0.184 (R-free 0.217). 97.4% of the residues are in the core regions
of the Ramachandran plot, and no residues are in disallowed
regions. All data collection and refinement statistics are summa-
rized in Table 1. The coordinates have been deposited in the
Protein Data Bank (accession codes 2v6q, 2wh6, 2xpx). Figures
were prepared using PyMol (DeLano Scientific).
Mouse tumor model
Em-myc transgenic mice on an inbred C57BL/6 background
with clinical evidence of lymphoma were culled by CO2
asphyxiation and lymphomatous tissue excised. Single-cell sus-
pensions were obtained by manual sieving and stable Em-myc
tumor cell cultures were established in FMA medium. Retroviral
transduction using a pMSCV-IRES-GFP vector containing
BHRF1 or Bcl-2 and sorting of GFP positive cells were conducted
as previously described [11]. 1610
6 viable tumor cells in 100 mL
PBS were injected intraperitoneally into syngeneic C57BL/6 mice.
Ara-C or PBS was injected intraperitoneally in 100 mL total
volume on days 4, 5 and 6. Mice were culled when sick (hindleg
paralysis, tremor, lethargic, tumor nodule .1 cm diameter, .5%
weight loss) and leukemia/lymphoma confirmed by the presence
of peripheral blood leucocytosis and enlarged spleen and/or
lymph nodes. Survival of cohorts of 5 mice was compared by log-
rank test and Kaplan-Meier analysis using GraphPad Prism
statistical software. All experiments were approved by an
institutional ethics committee.
Cell lines and tissue culture
MEF, HEK-293T and Phoenix packaging 293 cells were
cultured in Dulbecco’s Modified Eagles medium (DMEM)
Figure 5. BHRF1 inhibits ABT-737 induced apoptosis and confers chemoresistance in a mouse model of Burkitt lymphoma.
(A) Colony formation of mcl-1
2/2 MEFs overexpressing BHRF1, Bcl-xL or a control vector, 6 d after treatment with 0-10 mM ABT-737. (B, C) Kaplan-
Meier survival plots of mice inoculated with Em-myc tumor cells overexpressing BHRF1, Bcl-2 (or an empty vector) and treated on d 4, 5 and 6 (arrows)
afterwards with (B) saline or (C) 100 mg/kg cytosine arabinoside (Ara-C; given intra-peritoneally). N=5 mice in each group. Expression of BHRF1 or
Bcl-2 conferred chemoresistance (p=0.014 and p=0.049 respectively by log-rank test when compared to saline treated controls). However, there is
no significant difference whether or not BHRF1 or Bcl-2 is expressed as a transgene (p=0.85 by log-rank test).
doi:10.1371/journal.ppat.1001236.g005
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supplemented with mouse IL-3 (1000 U/mL). Em-myc tumor cells
were harvested from a symptomatic Em-myc transgenic mouse and
cultured in FMA, a high glucose version of DMEM supplemented
with10%FCS, 50 mM 2-mercaptoethanoland250 mMasparagine.
Mammalian expression constructs
Epitope-tagged mammalian expression vectors for human Bcl-2
family proteins have been described previously [20,49,50,51,52].
All constructs were verified by sequencing. Details and constructs
are available from the authors.
Retrovirus production and transduction
To produce retroviral supernatant, 2.5610
6 ecotropic Phoenix
packaging cells were seeded overnight in 10 cm tissue culture
plates. Media was replaced with 5 ml serum-free DMEM
containing 5 mg MSCV-based retroviral plasmid with 15 mL
Lipofectamine (Invitrogen). After 24 h media was replaced with
medium supplemented with 20% FCS and incubated for a further
24 h at 32uC. Viral supernatant was cleared of cell debris by
centrifugation for 5 min at 1500 rpm. 500 mL filtered virus
(0.45 mm, Millipore) was spin-infected onto target cells in a total
volume of 1 mL media containing 4 mg/mL polybrene (Sigma) in
24 well plates at 32uC with 2500 rpm radial centrifugation for
45 min. Infection efficiency of MEFs were generally .90% and
20–30% for FDC-P1 cells.
Cell survival assays and cytotoxic drugs
Cell death was induced by 0–100 mM etoposide (Pharmacia-
Upjohn), 0–30 Gy c-irradiation, 0–10 mM Ara C (Pharmacia-
Upjohn), 0–100 nM staurosprorine (Sigma-Aldrich) or 0–10 mM
ABT-737 (Abbott Laboratories). Cell viability was quantified by
flow cytometric analysis of cells excluding 5 mg/mL propidium
iodide (PI) (Sigma-Aldrich) using a FACScan (Becton Dickinson).
Each time point was performed at least three times. For long-term
colony assays using MEFs, cells were infected with GFP-expressing
retroviral constructs, then treated with qVD.OPH (Enzyme
Systems) to prevent cell death. After culture for 24 h, 200 GFP
+ve
cells were sorted into 6-well plates. Colonies were stained and
counted 6 d later.
Immunofluorescence
Cells expressing mammalian FLAG-tagged pro-survival Bcl-2
proteins, BHRF1 or empty vector were washed in PBS, fixed in
1% paraformaldehyde/PBS (10 min, 4uC) and washed twice in
KDS-BSS. Cells were incubated with 1:1,000 primary anti-FLAG
M2 (Sigma) antibody for 20 minutes, washed in KDS-BSS/0.02%
saponin and then incubated with 1:100 goat anti-mouse FITC or
PE antibody (Southern Biotechnology) for 20 minutes before
analysis on a FACScan (BD) using Cell Quest software (BD).
Cytofluorometric determination of mitochondrial
transmembrane potential and Bax/Bak activation
To assess mitochondrial transmembrane potential (Dym), cells
were incubated for 15 min at 37uC in buffer containing 40 nM
3,39- dihexyloxacarbocyanine iodide (DiOC6[3]; Molecular
Probes) before adding 10 mg/mL of PI. The cells were kept on
ice until flow cytometric analysis. To assess the activation of Bax
and Bak, HeLa cells were left untreated or pretreated with a
proteasome inhibitor (10 mM MG-132; Calbiochem) or a wide-
spectrum caspase inhibitor (100 mM zVAD.fmk; Bachem) for 1 h
before treatment with 200 J/m
2 UV-irradiation. Following UV
irradiation, cells were fixed with 1% paraformaldehyde (5 min at
room temperature) and then washed with buffer supplemented
with 2% fetal bovine serum. Fixed cells were then incubated with
the primary antibodies: 2 mg/mL anti-Bak Ab-1 (Calbiochem) or
5 mg/mL anti-Bax clone 3 (BD) diluted in FACS buffer
supplemented with 0.3% saponin for 30 min on ice. Cells were
then washed, before incubation with the appropriate secondary
antibody, either FITC-conjugated goat-anti-mouse IgG (10 mg/
ml; SouthernBiotech) to detect Bax activation or a biotin-
conjugated anti-mouse (diluted 1:200; SouthernBiotech) followed
by Streptavidin-conjugated PE (diluted 1:300; Caltag) to detect
Bak activation. The samples were analyzed using a FACScan
(BD).
Subcellular fractionation
Fractionation of whole cell lysates into the soluble and pellet
fractions has been previously described [54]. In brief, cells lysed in
HMKEE buffer (20 mM Hepes, pH 7.2, 5 mM MgCl2, 10 mM
KCl, 1 mM EDTA, 1 mM EGTA, and protease inhibitors)
containing 250 mM sucrose and 0.025% digitonin (Calbiochem)
were left on ice for 10 min, and then the organelles, cytoskeleton,
and membranes were pelleted by centrifugation (13,000 rpm,
5 min at 4uC). The pellet was solubilized in RIPA buffer (150 mM
NaCl, 1% Triton X-100, 0.5% deoxycholic acid, 0.1% SDS,
50 mM Tris-HCl, pH 8.0, and protease inhibitors). The protease
inhibitors used include Pefabloc SC, soybean trypsin inhibitor,
leupeptin, aprotinin, E64, and pepstatin (Sigma-Aldrich or
Roche).
Transient transfection, immunoprecipitation and
immunoblotting
The transfection and metabolic labeling of HEK-293T cells
with
35S-methionine/cysteine (NEN) as well as co-immunoprecip-
itation have been described [49,50,52]. Briefly, equivalent TCA-
precipitable lysates were immunoprecipiated using the mouse
monoclonal antibodies to FLAG (M2; Sigma), Glu-Glu (CRP) and
control HA (HA.11; CRP) tags. The proteins were resolved by
SDS:PAGE, transferred onto nitrocellulose membranes and
detected by autoradiography after 20 h at 280uC. Immunoblot-
ting was performed using mouse monoclonal antibodies to Bax
(5B7; Sigma-Aldrich) cytochrome c (7H8.2C12; BD Pharmingen)
and detected using HRP-conjugated secondary antibodies (South-
ern Biotechnology) revealed by enhanced chemiluminescence
(ECL; Amersham Biosciences).
Yeast colony assays
Yeast expression vectors were made by subcloning the cDNAs
for full-length human Bcl-xL and BHRF1, or human Bax and
human Bak, respectively, into the pGALL(TRP1) and pGAL-
S(LEU2) vectors [55]. Saccharomyces cerevisiae W303a cells were co-
transformed with indicated plasmids and grown under selection.
For the survival assays, the cells were spotted as 5-fold serial
dilutions onto glucose (repressing, ‘‘OFF’’) or galactose (inducing,
‘‘ON’’) plates as previously described [28]. Plates were incubated
for 48 h at 30uC and then photographed.
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Health and Medical Research
Council. The protocol was approved by the Committee on the
Ethics of Animal Experiments of the Walter and Eliza Hall
Institute of Medical Research (Permit Number: NKOT_07_008).
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Supporting Information
Figure S1 Pre-B-cell tumor cells derived from Em-myc transgenic
mice were stably transfected with BHRF1, Bcl-2 or a control
vector and exposed to etoposide (0–10 mM). Viability was assessed
by PI staining after 24 h.
Found at: doi:10.1371/journal.ppat.1001236.s001 (0.17 MB TIF)
Figure S2 BHRF1 is not inhibited by ABT-737. Mcl-1 deficient
MEF stably expressing BHRF1, Bcl xL or a control vector were
treated with ABT-737 (0–10 mM). Viability was assessed 8 h later
by flow cytometry after propidium iodide staining.
Found at: doi:10.1371/journal.ppat.1001236.s002 (0.13 MB TIF)
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